A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus

  • Authors:
    • Huibiao Quan
    • Huachuan Zhang
    • Weiping Wei
    • Tuanyu Fang
    • Daoxiong Chen
    • Kaining Chen
  • View Affiliations

  • Published online on: August 2, 2017     https://doi.org/10.3892/etm.2017.4863
  • Pages: 3279-3287
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to explore the effects of various combinations of exenatide, metformin (MET) and biphasic insulin aspart 30 (BIA30) on type 2 diabetes mellitus (T2DM). Two hundred overweight or obese patients newly diagnosed with T2DM were evenly randomized into two groups: A (twice daily for all: Phase I, 5 µg exenatide + 0.5 g MET for 4 weeks, then 10 µg exenatide + 0.5 g MET for 8 weeks; Phase II, 0.5 g MET for 12 weeks; Phase III, 0.3‑0.4 U/kg/day BIA30 + 0.5 g MET for 12 weeks) and B (Phases I, II, III matched the phases III, II and I in group A). In groups A and B a significant decrease and increase, respectively, in glycated hemoglobin (HbAlc) and body mass index (BMI) was noted during Phase I. A 3.2±0.4‑kg decrease in body weight in group A and a 2.6±0.3‑kg increase in group B was observed. In Phase II, HbAlc was significantly increased in both groups (P<0.05). In Phase III, the BMI was increased in group A and reduced in group B (P<0.05). There was a 3.8±0.4‑kg weight decrease in group B and 4.2±0.5‑kg increase in group A (P<0.05). The combination of exenatide and MET promoted weight loss, glycemic control, β‑cell function index, C peptide and adiponectin levels. These results suggested that the combination of exenatide and MET is better than the combination of BIA and MET for the therapy of overweight or obese patients newly diagnosed with T2DM.

Related Articles

Journal Cover

October-2017
Volume 14 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Quan H, Zhang H, Wei W, Fang T, Chen D and Chen K: A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. Exp Ther Med 14: 3279-3287, 2017.
APA
Quan, H., Zhang, H., Wei, W., Fang, T., Chen, D., & Chen, K. (2017). A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. Experimental and Therapeutic Medicine, 14, 3279-3287. https://doi.org/10.3892/etm.2017.4863
MLA
Quan, H., Zhang, H., Wei, W., Fang, T., Chen, D., Chen, K."A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus". Experimental and Therapeutic Medicine 14.4 (2017): 3279-3287.
Chicago
Quan, H., Zhang, H., Wei, W., Fang, T., Chen, D., Chen, K."A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus". Experimental and Therapeutic Medicine 14, no. 4 (2017): 3279-3287. https://doi.org/10.3892/etm.2017.4863